Advanced search
Publication Cover
Biomarkers in Medicine Volume 5, 2011 - Issue 3
Submit an article Journal homepage
292
Views
2
CrossRef citations to date
0
Altmetric
Review

Update on HER2 Testing for Breast and Upper Gastrointestinal Tract Cancers

Jeffrey S RossFoundation Medicine Inc.,Cambridge,MA,USA and Department of Pathology & Laboratory Medicine,Albany Medical College,Department of Pathology,Mail Code 81, 47 New Scotland Avenue,Albany,NY 12208,USA. Correspondence[email protected]
Pages 307-318 | Published online: 09 Jun 2011

Bibliography

  • Ross JS , SlodkowskaEA, SymmansWFet al. : The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.Oncologist14, 320–368 (2009).
  • Press MF , HungG, GodolphinWet al. : Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.Cancer Res.54, 2771–2777 (1994).
  • Paik S , BryantJ, Tan-ChiuEet al. : Real-world performance of HER2 testing – National Surgical Adjuvant Breast and Bowel Project experience.J. Natl Cancer Inst.94, 852–854 (2002).
  • Paik S , Tan-chuiE, BryanJet al. : Successful quality assurance program for HER-2 testing in the NSAPB trial for Herceptin.J. Natl Cancer Inst.76(Suppl. 1), S31 (2002).
  • Dowsett M , HanbyAM, LaingR, WalkerR: National HER2 consultation steering group: HER2 testing in the UK: consensus from a national consultation.J. Clin. Pathol.60, 685–689 (2007).
  • Rhodes A , JasaniB, AndersonEet al. : Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin- processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries.Am. J. Clin. Pathol.118(3), 408–417 (2002).
  • Wang S , SaboorianMH, FrenkelEPet al. : Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard.Am. J. Clin. Pathol.116(4), 495–503 (2001).
  • Bloom KJ , Torre-BuenoJ, PressM, GownA, BauerK, HarringtonD: Comparison of HER-2/neu analysis using FISH and IHC when HercepTest is scored using conventional microscopy and image analysis.Breast Cancer Res. Treat.64, 99 (2000).
  • Seelig S : Fluorescence in situ hybridization versus immunohistochemistry: importance of clinical outcome.J. Clin. Oncol.17, 3690–3692 (1999).
  • Lal P , SalazarPA, HudisCAet al. : HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.Am. J. Clin. Pathol.121, 631–636 (2004).
  • Owens MA , HortenBC, Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin. Breast Cancer5, 63–69 (2004).
  • Press MF , SauterG, BernsteinLet al. : Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.Clin. Cancer Res.11, 6598–6607 (2005).
  • Tubbs RR , HicksDG, CookJet al. : Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarcinoma of the breast: a single institution experience.Diagn. Mol. Pathol.16, 207–210 (2007).
  • Ross JS , SymmansWF, PusztaiL, HortobagyiGN: Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes.Clin. Cancer Res.13, 2831–2835 (2007).
  • Bartlett JM , IbrahimM, JasaniBet al. : External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme.J. Clin. Pathol.60, 816–819 (2007).
  • Dendukuri N , KhetaniK, McIsaacM, BrophyJ: Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis.CMAJ176, 1429–1434 (2007).
  • Carlson RW , MoenchSJ, HammondMEet al. : HER2 testing in breast cancer: NCCN Task Force report and recommendations.J. Natl Compr. Canc. Netw.4(Suppl. 3), S1–S22 (2006).
  • Penault-Llorca F , BilousM, DowsettMet al. : Emerging technologies for assessing HER2 amplification.Am. J. Clin. Pathol.132, 539–548 (2009).
  • Francis GD , JonesMA, BeadleGFet al. : Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.Diagn. Mol. Pathol.18, 88–95 (2009).
  • Dietel M , EllisIO, HöflerHet al. : Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists.Virchows Arch.451, 19–25 (2007).
  • Bilous M , MoreyA, ArmesJet al. : Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.Pathology38, 120–124 (2006).
  • Hanna WM , KwokK: Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm.Mod. Pathol.19, 481–487 (2006).
  • van de Vijver M , BilousM, HannaWet al. : Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.Breast Cancer Res.9, R68 (2007).
  • Di Palma S , CollinsN, FaulkesCet al. : Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.J. Clin. Pathol.60, 1067–1068 (2007).
  • Downs-Kelly E , YoderBJ, StolerMet al. : The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study.Am. J. Surg. Pathol.29, 1221–1227 (2005).
  • Beser AR , TuzlaliS, GuzeyDet al. : HER-2, TOP2A and chromosome 17 alterations in breast cancer.Pathol Oncol Res.13, 180–185 (2007).
  • Torrisi R , RotmenszN, BagnardiVet al. : HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17.Eur. J. Cancer43, 2339–2344 (2007).
  • Hyun CL , LeeHE, KimKSet al. : The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.J. Clin. Pathol.61, 317–321 (2008).
  • Hofmann M , StossO, GaiserTet al. : Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) Phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.J. Clin. Pathol.61, 89–94 (2008).
  • Kaufman PA , BroadwaterG, Lezon-GeydaK: CALGB 150002: correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC).J. Clin. Oncol.25, 1009 (2007).
  • Ross JS : Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference?J. Clin. Oncol.28, 4293–4295 (2010).
  • Wolff AC , HammondME, SchwartzJNet al. : American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.Arch. Pathol. Lab. Med.131, 18 (2007).
  • Perez EA , ReinholzMM, HillmanDWet al. : HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.J. Clin. Oncol.28, 4307–4315 (2010).
  • Slamon DJ , ClarkGM, WongSGet al. : Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene.Science235, 177–182 (1987).
  • Tubbs RR , PettayJD, RochePCet al. : Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.J. Clin. Oncol.19, 2714–2721 (2001).
  • Millson A , SuliA, HartungLet al. : Comparison of two quantitative polymerase chain reaction methods for detecting HER-2/neu amplification.J. Mol. Diagnostics5, 184–190 (2003).
  • Suo Z , DaehliKU, LindboeCFet al. : Real-time PCR quantification of c-erbB-2 gene is an alternative for FISH in the clinical management of breast carcinoma patients.Int. J. Surg. Pathol.12, 311–318 (2004).
  • Bergqvist J , OhdJF, SmedsJet al. : Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome.Ann. Oncol.18, 845–850 (2007).
  • Barberis M , PellegriniC, CannoneMet al. : Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.Am. J. Clin. Pathol.129, 563–570 (2008).
  • Paik S , ShakS, TangGet al. : A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.N. Engl. J. Med.351, 2817–2826 (2004).
  • Ross JS , HatzisC, SymmansWFet al. : Commercialized multigene predictors of clinical outcome for breast cancer.Oncologist13, 477–493 (2008).
  • Baehner FL , AchacosoN, MaddalaTet al. : Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.J. Clin. Oncol.28, 4300–4306 (2010).
  • Gong Y , YanK, LinFet al. : Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.Lancet Oncol.8, 203–211 (2007).
  • Bates MP , DesmedtC, SperindeJet al. : Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2–HER2 dimerization in a clinic-based cohort of patients with metastatic breast cancer.J. Clin. Oncol.25, 10557 (2007).
  • Toi M , SperindeJ, HuangWet al. : Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2:HER2 dimerization in a clinic-based cohort of patients with metastatic breast cancer.J. Clin. Oncol.25, 1025 (2007).
  • Toi M , SperindeJ, HuangWet al. : Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer.BMC Cancer10, 56 (2010).
  • Thor AD . LiuS. EdgertonS. MooreDet al.: Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J. Clin. Oncol.18, 3230–3239 (2000).
  • DiGiovanna MP , ChuP, DavisonTLet al. : Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates.Cancer Res.62, 6667–6673 (2002).
  • Carney WP , NeumannR, LiptonAet al. : Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.Clin. Breast Cancer5, 105–116 (2004).
  • Fornier MN , SeidmanAD, SchwartzMKet al. : Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.Ann. Oncol.16, 234–239 (2005).
  • Shiu KK , NatrajanR, GeyerFC, AshworthA, Reis-FilhoJS: DNA amplifications in breast cancer: genotypic-phenotypic correlations.Future Oncol.6, 967–984 (2010).
  • Schweiger MR , KerickM, TimmermannBet al. : The power of NGS technologies to delineate the genome organization in cancer: from mutations to structural variations and epigenetic alterations.Cancer Metastasis Rev.30(2), 199–210 (2011).
  • Cristofanilli M , BuddGT, EllisMJet al. : Circulating tumor cells, disease progression, and survival in metastatic breast cancer.N. Engl. J. Med.351, 781–791 (2004).
  • Riethdorf S , WikmanH, PantelK: Biological relevance of disseminated tumor cells in cancer patients.Int. J. Cancer123, 1991–2006 (2008).
  • Wülfing P , BorchardJ, BuergerHet al. : HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.Clin. Cancer Res.12, 1715–1720 (2006).
  • Tewes M , AktasB, WeltAet al. : Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.Breast Cancer Res. Treat.115(3), 581–590 (2009).
  • Ignatiadis M , KallergiG, NtouliaMet al. : Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.Clin. Cancer Res.14, 2593–2600 (2008).
  • Lang JE , MosalpuriaK, CristofanilliMet al. : HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer.Breast Cancer Res. Treat.113(3), 501–507 (2009).
  • Punnoose EA , AtwalSK, SpoerkeJMet al. : Molecular biomarker analyses using circulating tumor cells.PLoS One5(9), E12517 (2010).
  • Jemal A , SiegalR, XuJet al. : Cancer statistics, 2010.CA Cancer J. Clin.60, 277–300 (2010).
  • Shah MA , KelsenDP: Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease.J. Natl Compr. Canc. Netw.8, 437–447 (2010).
  • Hasegawa S , YoshikawaT: Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies.Gastric Cancer13, 63–73 (2010).
  • Resende C , RistimäkiA, MachadoJC: Genetic and epigenetic alteration in gastric carcinogenesis.Helicobacter.15(Suppl. 1), 34–39 (2010).
  • Lehmann K , SchneiderPM: Differences in the molecular biology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third.Recent Results Cancer Res.182, 65–72 (2010).
  • Power DG , KelsenDP, ShahMA: Advanced gastric cancer – slow but steady progress.Cancer Treat Rev.36, 384–392 (2010).
  • Van Cutsem E , MoiseyenkoVM, TjulandinSet al. : Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.J. Clin. Oncol.24, 4991–4997 (2006).
  • Cunningham D , StarlingN, RaoSet al. : Capecitabine and oxaliplatin for advanced esophagogastric cancer.N. Engl. J. Med.358, 36–46 (2008).
  • Ross JS , McKennaBJ: The HER-2/neu oncogene in tumors of the gastrointestinal tract.Cancer Invest.19, 554–568 (2001).
  • Thompson SK , SullivanTR, DaviesRet al. : HER-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.Ann. Surg. Oncol. (2011) (Epub ahead of print).
  • Albarello L , PecciariniL, DoglioniC: HER2 testing in gastric cancer.Adv. Anat. Pathol.18, 53–59 (2011).
  • De Vita F , GiulianiF, SilvestrisNet al. : Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.Cancer Treat Rev.36(Suppl. 3), S11–S15 (2010).
  • Brien TP , OdzeRD, SheehanCEet al. : HER-2/neu gene amplification by FISH predicts poor survival in Barrett‘s esophagus-associated adenocarcinoma.Hum. Pathol.31, 35–39 (2000).
  • Yan B , YauEX, Bte Omar SS et al.: A study of HER2 gene amplification and protein expression in gastric cancer. J. Clin. Pathol.63, 839–842 (2010).
  • Rüschoff J , DietelM, BarettonGet al. : HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.Virchows Arch.457, 299–307 (2010).
  • Grabsch H , SivakumarS, GraySet al. : HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value – conclusions from 924 cases of two independent series.Cell Oncol.32, 57–65 (2010).
  • Thompson SK , SullivanTR, DaviesR, RuszkiewiczAR: HER-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.Ann. Surg. Oncol. DOI: 10.1245/s10434-011-1554-1 (2011) (Epub ahead of print).
  • Bang YJ , Van Cutsem E, Feyereislova A et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet376, 687–697 (2010).
  • Barros-Silva JD , LeitãoD, AfonsoL: Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients.Br. J. Cancer10, 487–493 (2009).
  • Boers JE , MeeuwissenH, MethorstN: HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).Histopathology58, 383–394 (2011).
  • Hofmann M , StossO, ShiDet al. : Assessment of a HER2 scoring system for gastric cancer: results from a validation study.Histopathology52, 797–805 (2008).
  • Bang Y , ChungH, XuJet al. : Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial.J. Clin. Oncol.27(Suppl. 15), 4556 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.